pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 1·1 min read
save

Biotech funding surge: 40 companies secure $100M+ rounds in H1 2026

Jul 1, 2026·read at Endpoints ↗DealPositive

Endpoints News reported that 40 private biotech firms announced funding rounds of at least $100 million each in the first half of 2026.

This count surpasses the number recorded for the same period in 2025, indicating a notable uptick in large-scale financing for the sector.

The surge, highlighted by a strong June, suggests continued investor appetite for biotech ventures as they advance pipelines and development programs.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “A June flourish lifts biotech megaround tally in first half of 2026”

read at Endpoints ↗
83 words · retrieved Jul 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Private Biotech2

related stories

  • 6d agoDeep-pocketed Verdiva axes GLP-1 switching trial over ‘market evolution’Fierce Biotech
  • 6d agoVerdiva cans mid-stage obesity trial of GLP-1 pill, citing 'market evolution'Endpoints
  • Oct 9This week in charts: What’s driving biotech’s recent pullback?BioPharma Dive
  • Sep 21Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&ABioSpace
  • Sep 17North Immunology goes public via reverse merger as eczema drug heads toward clinicFierce Biotech